Effect of vasoactive intestinal polypeptide (VIP) antagonism on rat jejunal fluid and electrolyte secretion induced by cholera and *Escherichia coli* enterotoxins

F H Mourad, C F Nassar

Abstract

**Background**—The enteric nervous system is important in the pathophysiology of intestinal fluid secretion induced by cholera toxin (CT), *Escherichia coli* heat labile (LT), and heat stable (STa) toxins. The neurotransmitters involved are not fully elucidated. Vasoactive intestinal polypeptide (VIP), a potent intestinal secretagogue present in the enteric nervous system, is increased after exposure of the cat intestine to CT. Whether VIP is involved in the pathogenesis of cholera and other toxins is not known.

**Aim**—To study in vivo the effect of VIP antagonism on jejunal fluid secretion induced by CT, LT, and STa.

**Methods**—CT, LT (25 µg), or 0.9% NaCl was instilled in an isolated 25 cm segment of rat jejunum, and the VIP antagonist (VIPa) [4Cl-D-Phe³, Leu⁷]-VIP (0.2 or 2 µg/kg/min) or 0.9% NaCl was given intravenously. Two hours later, single pass in vivo jejunal perfusion was performed to assess fluid movement. In STa experiments, intravenous VIPa or 0.9% NaCl was given and 30 minutes later the jejunal segment was perfused with a solution containing STa 200 µg/l.

**Results**—VIPa had no effect on basal intestinal fluid absorption. CT induced net fluid secretion (median −68 µl/min/g dry intestinal weight (interquartile range −80 to −56)) which was dose dependently reversed by VIPa (6.2 (−16 to 34) and 29 (17 to 42)); p<0.01. Similarly, LT induced secretion (−63 (−73 to −30)) was attenuated by VIPa (0.2 µg/kg/min) (−15 (−24 to −1)); p<0.01 and totally reversed to normal levels by VIPa (2 µg/kg/min) (37 (28 to 56)); p<0.01 compared with LT and not significantly compared with normal controls. STa induced secretion (−17 (−19 to −2)) was also reversed by VIPa (12 (9 to 23) and 14 (9 to 26)); p<0.01.

**Conclusion**—VIP plays an important role in CT, LT, and STa induced intestinal secretion and may be the final putative neurotransmitter in the pathophysiology of these toxins.

(Gut 2000;47:382–386)

Keywords: cholera toxin; *Escherichia coli* toxins; intestinal secretion; vasoactive intestinal polypeptide; enteric nervous system

Intestinal secretion induced by cholera toxin (CT) and the structurally related enterotoxin, *Escherichia coli* heat labile toxin (LT), has been attributed solely to direct activation of adenylate cyclase with a corresponding increase in intracellular cAMP. However, evidence has been accumulating on the importance of other mediators such as 5-hydroxytryptamine (5-HT), prostaglandins, neuropeptide, and of the enteric nervous system in the pathophysiology of CT induced secretion. In addition, vasoactive intestinal polypeptide (VIP) has been found to be released in response to administration of CT. VIP is present in high concentrations in the subepithelial neural plexuses and is a potent secretagogue which acts via specific adenylate cyclase linked receptors. For these reasons, it seems likely that VIP plays an important physiological and pathophysiological role in the intestine. The proposed mechanism for CT induced secretory diarrhoea includes a neural reflex with a common final pathway through VIP to the epithelial cells. However, this proposal remains to be confirmed in studies proving that VIP is important in the pathophysiology of CT induced secretion and is not just an innocent bystander.

The pathophysiology of diarrhoea caused by other enterotoxins has not been as extensively investigated. LT, which is structurally similar to CT, binds to the same receptor on enterocytes (GM1 ganglioside) and has been shown to stimulate adenylate cyclase with a corresponding increase in cAMP production. However, the two toxins are not identical in their amino acid composition and their binding affinity is different. In addition, we have previously demonstrated that 5-HT plays an important role in CT but not LT induced secretion suggesting that there are fundamental differences in the pathophysiology of fluid secretion caused by these toxins. Furthermore, Nzegwu and Levin have shown that intraluminal capsaicin inhibits LT induced secretion implying that LT acts through afferent nerve fibres. The neurotransmitters involved in the effenter loop of this neural reflex are not known. Whether VIP plays a role in LT...
VIP antagonism and jejunal fluid and electrolyte secretion induced by enterotoxins

induced secretion has not been previously investigated.

The role of cGMP in *Escherichia coli* heat stable toxin (STa) induced intestinal secretion is well established. It has been shown that, stable toxin (STa) induced intestinal secretion containing Na 140, K 4, Cl 104, and HCO3 40 with a plasma electrolyte solution (PES) after two hours the clamps were removed and abdominal cavity and the abdomen closed. Cannulae. The intestine was returned to the by clamping of both the proximal and distal was instilled in the isolated segments followed

Net fluid secretion occurred in all animals who received CT (−68 µl/min/g (−80 to −56), n=7) to which 200 µg/l of ST (equivalent to 50 000 mouse units) were added. After 30 minutes of perfusion to establish a steady state, consecutive 10 minute collections of the effluent were obtained for one hour. Infusion of the VIP antagonist or 0.9% NaCl was started 30 minutes before the perfusion.

**VIP experiments**

In a different group of animals, both femoral veins were cannulated. VIPa infusion (0.2 or 2 µg/kg/min) was started in one femoral vein and 30 minutes later VIP infusion (0.02 or 0.2 µg/kg/min) was started in the second femoral vein. One hour later, intestinal perfusion was performed as mentioned above to calculate fluid and electrolyte movement.

In a different group of animals, the effect of VIPa (2 µg/kg/min) on intestinal secretion induced by 1 mM carbachol added to the perfusate was tested.

Steady state conditions in all experiments were demonstrated by less than 5% variation in fluid movement between consecutive 10 minute collections. Also, values were accepted only if recovery of radioactive PEG was 95–105%.

**ANALYTICAL METHODS**

[14C]-PEG concentrations in the effluent were measured in duplicate by liquid scintillation spectroscopy in an LKB Wallac 1409 scintillation counter. Sodium and chloride concentrations were determined by an Hitachi 911 analyser.

The mean of net fluid and solute movement of six consecutive effluent samples were calculated and expressed, respectively, as µl/min/g and µmol/min/g of dry intestinal weight. Positive values denote net absorption and negative values net secretion.

**STATISTICS**

Results are expressed as median (interquartile range) in each group of animals studied. Differences in fluid and solute movement between pairs were tested using the Wilcoxon rank sum test.

**MATERIALS**

Cholera toxin, *Escherichia coli* heat stable and heat labile toxins, VIP, the VIP antagonist, and carbachol were obtained from Sigma Chemical Company (St Louis, Missouri, USA). Radiolabelled polyethylene glycol ([14C]-PEG 4000) was obtained from Amersham International (Buckinghamshire, UK) and all other chemicals were supplied by British Drug House (BDH Chemicals, Poole, UK).

**RESULTS**

Basal fluid absorption (median 61 µl/min/g (interquartile range 49–81); n=11) was not affected by the VIP antagonist at 0.2 or 2 µg/kg/min (48 (28–79), n=7, and 55 (34–75), n=6, respectively). Chloride and sodium movement paralleled that of fluid (table 1).

**CT and LT experiments**

Net fluid secretion occurred in all animals who received CT (−68 µl/min/g (−80 to −56), n=7)
Table 1  Effect of vasoactive intestinal polypeptide (VIP) antagonism on net Na+ and Cl− flux in normal controls, in cholera toxin (CT), Escherichia coli heat labile toxin (LT), and Escherichia heat stable toxin (STa) induced secretion, and on VIP induced decrease in absorption

<table>
<thead>
<tr>
<th></th>
<th>Net Cl− flux (µmol/min/g)</th>
<th>Net Na+ flux (µmol/min/g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VIPa0.2</td>
<td>2.8 (2.4 to 3.3)</td>
<td>6.7 (5.7 to 11.1)</td>
</tr>
<tr>
<td>VIPa2</td>
<td>3.5 (2.4 to 4.3)</td>
<td>7.1 (4.3 to 12.5)</td>
</tr>
<tr>
<td>CT</td>
<td>−13.1 (−14.6 to −9.9)</td>
<td>−7.9 (−10.9 to −6.5)</td>
</tr>
<tr>
<td>VIPa0.2</td>
<td>−3.3 (−4.3 to −1.5)</td>
<td>−1.5 (−2.3 to 2.3)</td>
</tr>
<tr>
<td>VIPa2</td>
<td>−1.2 (−4.2 to −3)</td>
<td>−0.5 (−3.5 to −1.5)</td>
</tr>
<tr>
<td>LT</td>
<td>−10.6 (−12 to −9.5)</td>
<td>−8.5 (−12.2 to −7.2)</td>
</tr>
<tr>
<td>VIPa0.2</td>
<td>−7.6 (−12.6 to −1.5)</td>
<td>−2.2 (−6.5 to −1.5)</td>
</tr>
<tr>
<td>VIPa2</td>
<td>−1 (−2.5 to 0.5)</td>
<td>1.3 (3.5 to 5.0)</td>
</tr>
<tr>
<td>STa</td>
<td>−10 (−15 to −5.3)</td>
<td>−7 (−9.2 to −4)</td>
</tr>
<tr>
<td>VIPa0.2</td>
<td>−4.5 (−4.5 to 0)</td>
<td>−10 (−4.5 to 0)</td>
</tr>
<tr>
<td>VIPa2</td>
<td>−2.2 (−3.2 to 0.5)</td>
<td>−1.5 (−3.5 to 0)</td>
</tr>
<tr>
<td>VIP0.02</td>
<td>1.2 (0.5 to 2.1)</td>
<td>3.4 (2.2 to 5.1)</td>
</tr>
<tr>
<td>VIPa2</td>
<td>2.6 (2.2 to 4)</td>
<td>6 (5 to 10.2)</td>
</tr>
<tr>
<td>VIPa0.2</td>
<td>2.9 (2.2 to 3.8)</td>
<td>7 (6.5 to 9.8)</td>
</tr>
<tr>
<td>VIP0.2</td>
<td>−1 (−1.9 to 1.1)</td>
<td>0 (0 to 2.1)</td>
</tr>
<tr>
<td>VIPa2</td>
<td>1.9 (1.3 to 2.2)</td>
<td>3.1 (2.5 to 4.5)</td>
</tr>
<tr>
<td>VIP0.2</td>
<td>3.2 (2.5 to 4.1)</td>
<td>6.3 (5.2 to 10)</td>
</tr>
</tbody>
</table>

Data are median (interquartile range). VIPa0.2, VIPa2, VIP antagonist [4Cl-D-Phe6, Leu17]VIP at a dose of 0.2 (VIPa0.2) or 2 µg/kg/min (VIPa2).

Fluid absorption and negative values denote secretion. **p<0.01 compared with controls; ††p<0.01 compared with CT and LT, and not significant compared with VIPa0.2. Chloride and sodium secretion were also significantly reduced in a dose dependent manner by the VIP antagonist (table 1).

VIP EXPERIMENTS

Fluid absorption in normal controls was significantly decreased by intravenous VIP at a dose of 0.02 µg/kg/min (28 (22–40), n=5; p<0.05). VIPa0.2 and VIPa2 completely abolished the effect of VIP (59 (42–71), n=5, and 62 (28–59), n=5). VIP at a dose of 0.2 µg/kg/min caused a further decrease in fluid absorption (8 (2–20), n=5) which was partially attenuated by VIPa0.2 (32 (23–38), n=5; p<0.05 compared with VIP), and completely prevented by VIPa2 (53 (40–61), n=5; p<0.05 compared with VIP and not significant compared with normal controls) (fig 2).

Carbachol induced fluid secretion (-17 (-19 to -9), n=4) was not affected by VIPa2 (-22 (-25 to -14)).

Discussion

The present experiments demonstrate that VIP plays an important role in intestinal fluid and electrolyte secretion induced by CT and E coli enterotoxins. It has previously been shown that activation of the enteric nervous system is cru-

Figure 1  Effect of the VIP antagonist [4Cl-D-Phe6, Leu17]VIP given intravenously at a dose of 0.2 and 2 µg/kg/min (VIPa0.2 and VIPa2, respectively) on cholera toxin (CT) induced secretion. Results are expressed as median (interquartile range); positive values denote absorption and negative values denote secretion. **p<0.01 compared with controls; ††p<0.01 compared with CT and controls.

Figure 2  Effect of the VIP antagonist [4Cl-D-Phe6, Leu17]VIP given intravenously at a dose of 0.2 and 2 µg/kg/min (VIPa0.2 and VIPa2, respectively) on Escherichia coli heat labile toxin (LT) induced secretion. Results are expressed as median (interquartile range); positive values denote absorption and negative values denote secretion. **p<0.01 compared with controls; ††p<0.01 compared with LT and controls; †‡p<0.01 compared with LT and p<0.05 compared with controls.

Figure 3  Effect of the VIP antagonist [4Cl-D-Phe6, Leu17]VIP given intravenously at a dose of 0.2 and 2 µg/kg/min (VIPa0.2 and VIPa2, respectively) on Escherichia coli heat stable toxin (STa) induced secretion. Results are expressed as median (interquartile range); positive values denote absorption and negative values denote secretion. *p<0.01 compared with controls; ††p<0.01 compared with VIP and not significant compared with normal controls.

www.gutjnl.com
VIP antagonism and jejunal fluid and electrolyte secretion induced by enterotoxins

...VIP antagonism dose dependently decreased fluid secretion induced by CT and partially reversed it to absorption, implying that VIP plays an important role in CT induced secretion but some other mediators may also be involved.

LT is a toxin structurally similar to CT and was thought to act via the same pathways. However, recent evidence suggests that these two toxins, although both stimulate adenylate cyclase, have totally different pathophysiological mechanisms. It has been shown definitively that 5-HT is not involved in LT induced secretion. In addition, blocking substance P receptors does not affect LT induced secretion. Hence, how does LT stimulate secretion? LT activates intracellular cAMP but this does not explain inhibition of secretion by neuronal blockade. By binding to some receptor sites on enterocytes, it may release an unknown transmitter which activates the neuronal reflex. Alternatively, it has been postulated that the toxin may bind directly to enteric neurones and thus activate secretion. Although the afferent capsaicin sensitive neurones are stimulated during LT exposure, it is not known if LT binds directly to these neurones. Cholera toxin B subunit was found to bind to specific receptors exclusively on VIP containing neurones; however, there are no such data for LT. In the present experiments, we demonstrated that VIP plays an important role in this secretory process as VIP antagonism completely prevented LT induced secretion.

STa is structurally different from the two other toxins and induces intestinal secretion through an increase in cGMP. In addition, it has been demonstrated that, in common with CT and LT, the enteric nervous system is important in STa induced secretion as shown by the inhibitory effect of neuronal blockade. The neuronal mediators involved have not been fully elucidated. 5-HT was not found to be implicated in STa induced secretion.
secretion. However, Rolfe and Levin have recently shown that nitric oxide synthase inhibition as well as capsaicin inhibit STa secretion in the rat ileum and concluded that STa activates a nitric oxide dependent myenteric plexus secretory reflex mediated by capsaicin sensitive C fibres. In addition, it seems that tachykinin NK2 receptors are activated to induce secretion during STa exposure. In the present experiments, VIP antagonism partially prevented STa-induced secretion demonstrating that VIPergic periganglionic neurons are activated during STa-induced secretion. VIPergic neurons and nitric oxide synthase containing neurones coexist in the enteric nervous system. In addition, nitric oxide may release VIP from nerve terminals, and VIP may cause release of nitric oxide. Thus we may speculate that nitric oxide and VIP interact to induce secretion in STa. This speculation needs to be confirmed in further studies.

In conclusion, our findings support the view that VIP participates in cholera toxin and E.coli enterotoxin induced secretion, presumably through activation of an effenter limb of the secretory neuronal reflex. These findings may have clinical applications in the future when VIP antagonists for human use become available.

Effect of vasoactive intestinal polypeptide (VIP) antagonism on rat jejunal fluid and electrolyte secretion induced by cholera and *Escherichia coli* enterotoxins

F H Mourad and C F Nassar

*Gut* 2000 47: 382-386
doi: 10.1136/gut.47.3.382

Updated information and services can be found at: [http://gut.bmj.com/content/47/3/382](http://gut.bmj.com/content/47/3/382)

These include:

**References**

This article cites 43 articles, 14 of which you can access for free at: [http://gut.bmj.com/content/47/3/382#BIBL](http://gut.bmj.com/content/47/3/382#BIBL)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)